Deals
CVC to Explore Options for $4 Billion Drugmaker Alvogen
- Shanghai Pharma holds on-and-off talks on potential purchase
- Discussions center on generic pharma company’s U.S. operations
Tablets
Photographer: Stefano Buonamici/BloombergThis article is for subscribers only.
Alvogen’s private equity owners including CVC Capital Partners are exploring options for the generic pharmaceutical company, which could be valued at about $4 billion, according to people familiar with the matter.
The controlling shareholders of the drugmaker have held on-and-off talks with Shanghai Pharmaceuticals Holding Co. focusing on a sale of Alvogen’s U.S. business, the people said. Alvogen would keep its operations in Asia as well as central and eastern Europe, one of the people said, asking not to be identified because the information is private.